Physician profile
Mark P Schopper
NPI 1033104658
$7,803.74
in general payments reported to CMS, 2019-2025
41 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $748 · 2021: $1,246 · 2022: $961 · 2023: $1,150 · 2024: $1,473 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,301.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $773.00 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $757.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $596.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $425.31 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $394.70 | 2021-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $292.06 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $281.96 | 2019-2023 | Xarelto |
| Amgen INC. | $266.90 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $237.79 | 2021-2024 | |
| Allergan, INC. | $236.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.45 | 2019-2024 | Jardiance |
| Paratek Pharmaceuticals, INC. | $187.60 | 2022-2023 | Nuzyra |
| Exact Sciences Corporation | $167.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $141.14 | 2019-2023 | Myrbetriq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.